DIS-CHEM PHARMACIES LIMITED - Directorate Change
What this filing means
Dis-Chem has appointed Clifford Raphiri as an independent non-executive director effective 21 September 2026, adding him to the Social and Ethics and Remuneration and Nomination sub-committees. The board confirms a fit and proper assessment was conducted and is satisfied with the outcome. The filing also carries a mandatory integrity disclosure: Raphiri was a director of Murray and Roberts Holdings when its operating company entered business rescue in November 2024, and he resigned roughly two months later. That disclosure is the one fact that makes this more than a routine appointment.
Dis-Chem is adding a new independent director to its board, which is normally routine governance news. What makes this one worth reading is the required disclosure that the new director sat on the board of a company whose operating subsidiary went into business rescue in late 2024, and he left that board about two months later. The filing does not explain the circumstances, so shareholders are left with a governance question the company has not answered.
Bear case
- The mandatory integrity disclosure flags that Raphiri was a director of Murray and Roberts Holdings when its operating subsidiary entered business rescue in November 2024 — a governance red flag newly introduced to the Dis-Chem board.
AI-generated summary by SENS-AI, based on the original JSE SENS filing.
SENS-AI conclusion
A routine board appointment with one non-routine element. The appointment itself is ordinary governance news — an independent non-executive director with relevant qualifications joining two sub-committees. The mandatory integrity disclosure is the only part that carries weight: a prior directorship at a company whose operating subsidiary entered business rescue, followed by a resignation two months later, with no explanation offered. That is a governance question, not a financial event, and it does not change the investment case on its own. So what: the board has added independent capacity, but the market still needs clarity on the circumstances around Raphiri's departure from Murray and Roberts Holdings.
The next governance disclosure is where shareholders will look for any further detail on the Murray and Roberts business rescue connection.
Evidence from the filing
The mandatory integrity disclosure flags that Raphiri was a director of Murray and Roberts Holdings when its operating subsidiary entered business rescue in November 2024 — a governance red flag newly introduced to the Dis-Chem board.
“shareholders are advised that there are no positive statements in respect of the integrity information contained in the director's declaration other than that Clifford was a director of Murray and Roberts Holdings when the operating company, Murray and Roberts Limited was placed into business rescue in November 2024”
More on Dis-Chem Pharmacies Limited
Related filings
More from DCP
Other Board Change
- NPNNASPERS LIMITED - Changes to the Composition of the Audit and Risk Committees
- RICHEFOND CIRCLE (RF) LIMITED - Richefond Circle (RF) Limited changes to the board
- HARCOURT STREET 1 (RF) LIMITED - Harcourt Street 1 (RF) Limited changes to the board
- MW ASSET RENTALS (RF) LIMITED - MWSI - MW Asset Rentals - Changes to the Board
- AFRICAN BANK HOLDINGS LIMITED - ABL ABHL - Changes to the Board of Directors of African Bank Limited And African Bank Holdings Limited